#### UNITED STATES BANKRUPTCY COURT

_	DISTRIC	Γ OF Delaware
In Re. Zosano Pharma Corporation	\$ \$ \$	Case No. 22-10506
Debtor(s)		☐ Jointly Administered
Monthly Operating Report	rt	Chapter 11
Reporting Period Ended: 08/31/2022		Petition Date: <u>06/01/2022</u>
Months Pending: 3		Industry Classification: 3 2 5 4
Reporting Method:	Accrual Basis •	Cash Basis
Debtor's Full-Time Employees (current)	):	3
Debtor's Full-Time Employees (as of da	te of order for relief):	15
Statement of cash receipts and cash rec	lisbursements mmary and detail of the asset or loss statement) sionals cs	
/s/ Dennis A. Meloro Signature of Responsible Party 09/22/2022 Date		Dennis A. Meloro (DE No. 4435) Printed Name of Responsible Party  1007 N. Orange St., Suite 1200, Wilmington, DE 19801
		Address

1

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore § 1320.4(a)(2) applies.



Pa	rt 1: Cash Receipts and Disbursements	<b>Current Month</b>	Cumulative
a.	Cash balance beginning of month	\$4,823,978	
b.	Total receipts (net of transfers between accounts)	\$1,000,004	\$1,376,285
c.	Total disbursements (net of transfers between accounts)	\$322,493	\$1,602,242
d.	Cash balance end of month (a+b-c)	\$5,501,488	· · · · · · · · · · · · · · · · · · ·
e.	Disbursements made by third party for the benefit of the estate	\$0	\$0
f.	Total disbursements for quarterly fee calculation (c+e)	\$322,493	\$1,602,242
	rt 2: Asset and Liability Status ot generally applicable to Individual Debtors. See Instructions.)	<b>Current Month</b>	
a.	Accounts receivable (total net of allowance)	\$0	
b.	Accounts receivable over 90 days outstanding (net of allowance)	\$0	
c.	Inventory (Book • Market Other (attach explanation))	\$0	
d	Total current assets	\$5,731,811	
e.	Total assets	\$6,189,258	
f.	Postpetition payables (excluding taxes)	\$909,292	
g.	Postpetition payables past due (excluding taxes)	\$573,210	
h.	Postpetition taxes payable	\$0	
i.	Postpetition taxes past due	\$0	
	Total postpetition debt (f+h)	\$909,292	
j.	Prepetition secured debt	\$909,292	
k.	-	\$37,729	
1.	Prepetition priority debt		
m.	Prepetition unsecured debt	\$11,527,807	
n.	Total liabilities (debt) (j+k+l+m)	\$12,474,827	
0.	Ending equity/net worth (e-n)	\$-6,285,570	
Pa	rt 3: Assets Sold or Transferred	<b>Current Month</b>	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary	\$0	\$2,950
b.	course of business  Total payments to third parties incident to assets being sold/transferred		\$2,930
	outside the ordinary course of business	\$0	\$0
c.	Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$2,950
Pa	rt 4: Income Statement (Statement of Operations)	<b>Current Month</b>	Cumulative
	ot generally applicable to Individual Debtors. See Instructions.)		
a.	Gross income/sales (net of returns and allowances)	\$0	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	\$0	
c.	Gross profit (a-b)	\$0	
d.	Selling expenses	\$0	
e.	General and administrative expenses	\$3,300,699	
f.	Other expenses	\$9,283,959	
g.	Depreciation and/or amortization (not included in 4b)	\$10,951	
h.	Interest	\$53	
i.	Taxes (local, state, and federal)	\$0	
j.	Reorganization items	\$263,380	h 12 10 <b>2</b> 00=
k.	Profit (loss)	\$-12,859,042	\$-16,492,085

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

			Approved	Approved	Paid Current	Paid
			Current Month	Cumulative	Month	Cumulative
	or's professional fees & expenses (bankı	ruptcy) Aggregate Total	\$0	\$0	\$108,709	\$108,70
Itemi	ized Breakdown by Firm	Г				
		Role				
i	KURTZMAN CARSON CONS	Other	\$0	\$0	\$108,709	\$108,70
ii						
iii						
iv						
v						
vi						
vii						
viii						
ix						
X						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii	i					
xix						
xx						
xxi						
xxii						
xxiii	i					
xxiv	7					
xxv						
xxvi	i					
xxvi	ii					
xxvi						
xxix						
XXX						
xxxi						
xxxi						
xxxi						
xxxi						
-						
XXXV						

Case 22-10506-JKS Doc 206 Filed 09/22/22 Page 4 of 13 Debtor's Name Zosano Pharma Corporation Case No. 22-10506 lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxv: lxxxv lxxxv lxxxix хc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Paid Current Paid Approved Current Month Cumulative Month Cumulative \$0 \$0 \$0 \$0 b. Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role \$0 \$0 \$0 \$0 ii iii iv vi vii viii ix Х

хi xii xiii xiv

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

		1	T	1
xv				
xvi				
xvii				
xviii				
xix				
xx				
xxi				
xxii				
xxiii				
xxiv				
xxv				
xxvi				
xxvii				
xxviii				
xxix				
xxx				
xxxi				
xxxii				
xxxiii				
xxxiv				
xxxv				
xxxvi				
xxxvii				
xxxvii				
xxxix				
xl				
xli				
xlii				
xliii				
xliv				
xlv				
xlvi				
xlvii				
xlviii				
xlix				
1				
li				
lii				
liii				
liv				
lv				
lvi				

# Case 22-10506-JKS Doc 206 Filed 09/22/22 Page 6 of 13

Debtor's	Name	Zosano Pharma Corporation			Ca	ase No. 22-1050	. 22-10506			
	xcix									
	С									
c.	All pro	ofessional fees and expenses (de	btor & committees)	\$0	\$0	\$0	\$0			

Pa	rt 6: Postpetition Taxes		Cur	rent Month	Cumulative
a.	Postpetition income taxes a	ccrued (local, state, and federal)		\$0	\$0
b.	Postpetition income taxes p	aid (local, state, and federal)		\$0	\$0
c.	Postpetition employer payro	oll taxes accrued		\$0	\$0
d.	Postpetition employer payro	oll taxes paid		\$5,034	\$25,660
e.	Postpetition property taxes	paid		\$0	\$0
f.	Postpetition other taxes acc	rued (local, state, and federal)		\$0	\$0
g.	Postpetition other taxes paid	d (local, state, and federal)		\$0	\$0
Pa	rt 7: Questionnaire - During	g this reporting period:			
a.	Were any payments made o	n prepetition debt? (if yes, see Instructions)	Yes •	No 🔿	
b.	Were any payments made o without court approval? (if	utside the ordinary course of business yes, see Instructions)	Yes 🔿	No 💿	
c.	Were any payments made to	or on behalf of insiders?	Yes •	No 🔘	
d.	Are you current on postpetit	tion tax return filings?	Yes •	No 🔘	
e.	Are you current on postpetit	tion estimated tax payments?	Yes •	No 🔘	
f.	Were all trust fund taxes rer	mitted on a current basis?	Yes •	No 🔘	
g.	Was there any postpetition by (if yes, see Instructions)	porrowing, other than trade credit?	Yes 🔿	No 💿	
h.	Were all payments made to the court?	or on behalf of professionals approved by	Yes 🔿	No   N/A	
i.	Do you have: Worl	ker's compensation insurance?	Yes •	No 🔘	
	1	If yes, are your premiums current?	Yes •	No O N/A O	(if no, see Instructions)
	Casu	alty/property insurance?	Yes •	No 🔘	
	1	If yes, are your premiums current?	Yes •	No O N/A O	(if no, see Instructions)
	Gene	eral liability insurance?	Yes 💿	No 🔘	
	]	If yes, are your premiums current?	Yes •	No O N/A O	(if no, see Instructions)
j.	Has a plan of reorganization	been filed with the court?	Yes •	No 🔘	
k.	Has a disclosure statement b	peen filed with the court?	Yes •	No 🔘	
1.	Are you current with quarte set forth under 28 U.S.C.		Yes •	No C	

### 

Deb	otor's Name Zosano Pharma Corporation	Case No.	22-10506					
	•							
Par	rt 8: Individual Chapter 11 Debtors (Only)							
a.	Gross income (receipts) from salary and wages	\$0						
b.	Gross income (receipts) from self-employment	\$0						
c.	Gross income from all other sources	\$0						
d.	Total income in the reporting period (a+b+c)	\$0						
e.	Payroll deductions	\$0						
f.	Self-employment related expenses	\$0						
g.	Living expenses	\$0						
h.	All other expenses	\$0						
i.	Total expenses in the reporting period (e+f+g+h)	\$0						
j.	Difference between total income and total expenses (d-i)	\$0						
k.	List the total amount of all postpetition debts that are past due	\$0						
1.	Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)?	Yes O No •						
m.	If yes, have you made all Domestic Support Obligation payments?	Yes O No N/A •						
thr bei is i lav ma Ex Re wv con	§§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).  I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the							
/s/ Sign	nature of Responsible Party Printe	en Lo d Name of Responsible Party 2/2022						
Titl	e Date							



# **Balance Sheet**

9/13/2022

10:18:12

	USD
Report Analysis Code	08-2022 Closing Balance
Assets	Dalance
Current assets	
Cash and cash equivalents	
10012 Cash, SVB ZPC Checking	4,992,242.63
10013 Cash, SVB (IGOE Admin)	51,798.09
TOTAL Cash and cash equivalents	5,044,040.72
Inventory	
12100 Raw Material Inventory	967,435.52
12199 Pre-Launch Inv-Reserve	(967,435.52)
TOTAL Inventory	0.00
Prepaid expenses and other current assets	
11160 Accounts Rec - Other	261,148.43
13111 Short-Term Deposits	4,689.73
13131 Prepaid Exp, Insurance	30,057.15
13181 Prepaid Expenses, Other	169,873.57
13182 Prepaid Software - ST	172,644.25
14000 Other Current Assets	49,356.70
TOTAL Prepaid expenses and other current assets	687,769.83
TOTAL Current assets	5,731,810.55
Restricted cash	
Restricted cash	
10120 Restricted Cash	457,447.48
TOTAL Restricted cash	457,447.48
TOTAL Restricted cash	457,447.48
Property and equipment, net	
Property and equipment	
16211 Manufacturing Equipment	11,572,297.37
16221 MFG Equip, Tools/Dies	3,515,445.03
16311 Furniture & Fixtures	98,901.70
16411 Office Equipment	45,736.00
16413 Office Equipment - Lease	24,604.00
16511 Laboratory Equipment	1,374,574.67
16611 Computer Equipment	135,398.04
16652 Computers - Leased	18,712.89
16711 Software	34,436.38
16811 Leasehold Improvements	18,074,362.00
16915 Fixed Assets Clearing	(451,891.46)
16916 Mfg Equip - Clearing	(11,572,297.37)
16917 MfgTools/Dies - Clearing	(3,515,445.13)
16918 Furn & Fixt - Clearing	(98,901.70)

16010 Lab Equip Clearing	(1 274 574 67)
16919 Lab Equip - Clearing 16920 Comptr Equip - Clearing	(1,374,574.67) (135,398.04)
TOTAL Property and equipment	17,745,959.71
Accumulated depreciation	17,743,939.71
17211 Accum Depr, MFG Equip	(9,848,160.67)
17221 Accum Depr, Tools/Dies	(1,593,344.98)
17311 Accum Depr, Furn & Fixt	(45,209.26)
17411 Accum Depr, Office Equip	(45,736.00)
17413 Accum Depr, OE - Leased	(24,604.00)
17511 Accum Depr, Lab Equip	(998,161.83)
17611 Accum Depr, Comp Equip	(115,760.18)
17652 Accum Depr. Comp - Lease	(18,712.89)
17711 Accum Depr, Software	(33,787.85)
17811 Accum Depr, LH Improv	(17,761,858.25)
17915 Accum Depr, Clearing	138,739.12
17916 AccDep MfgEqu - Clearing	9,848,160.67
17917 AccDep Tool/Die-Clearing	1,593,344.98
17918 AccDep Furn/Fix - Cleari	45,209.26
17919 AccDep LabEquip-Clearing	998,161.83
17920 AccDep Comptr - Clearing	115,760.18
TOTAL Accumulated depreciation	(17,745,959.87)
TOTAL Property and equipment, net	(0.16)
Deferred tax assets	(0.10)
Deferred tax assets	
19910 Deferred Tax Asset	39,380,141.00
19911 Def. Tax Asset Allowance	(38,458,373.00)
19912 Deferred tax liability	(921,768.00)
TOTAL Deferred tax assets	0.00
TOTAL Assets	6,189,257.87
Liabilities & Equity	0,103,237.07
Liabilities	
Current liabilities	
Accounts payable	
20100 Accounts Payable (Trade)	6,388,385.10
20120 AP - Unvouchered/Adj	248,993.79
TOTAL Accounts payable	6,637,378.88
Accrued compensation	0,007,070.00
21100 Wage/Severance Payable	4,300.00
21110 Vacation Liability	129,601.83
TOTAL Accrued compensation	133,901.83
Build-to-suit obligation, current portion	100,301.00
Operating lease liabilities, current portion	
22200 Operating Lease Liab-ST	1,671,759.09
· · · · · · · · · · · · · · · · · · ·	
TOTAL Operating lease liabilities, current portion	1,671,759.09
Other accrued liabilities	
20180 Miscellaneous Accrual	887,571.23
23200 Other ST Liability	1,071,935.48

25110 Legal - Accrual	59,296.05
25130 Use Tax Payable (CA)	0.00
TOTAL Other accrued liabilities	2,018,802.76
TOTAL Current liabilities	10,461,842.56
29230 Operating Lease Liab-LT	2,012,985.09
TOTAL Operating Lease Liabilities, long -term portion	2,012,985.09
TOTAL Liabilities	12,474,827.65
Equity	
Common stock	
31200 Common Stock (Par)	490.23
TOTAL Common stock	490.23
Additional paid In capital	
31111 APIC, Common	306,957,654.36
32213 APIC, Warrant	1,438,718.34
32223 Issuance Costs, Common	(12,822,167.57)
32233 Iss Costs, Common (IPO)	(5,895,000.97)
32251 Realized (Gain) Loss	120,309,803.89
32255 Unrealized FX Loss	(9,600.11)
TOTAL Additional paid In capital	409,979,407.94
Accumulated deficit	
39121 Retained Earnings CY	(54,150,709.31)
39123 Retained Earnings	(362,114,758.64)
TOTAL Accumulated deficit	(416,265,467.95)
Accumulated other comprehensive (income) loss	
TOTAL Equity	(6,285,569.78)
TOTAL Liabilities & Equity	6,189,257.87

#### ZOSANO PHARMA CORPORATION STATEMENT OF OPERATIONS (in thousands)

	Month of August 31, 2022	Cumulative Post-Petitio			
	(unaudited)	(unaudited)			
Service revenue	\$ -	\$	(6)		
Operating expenses:					
Cost of service revenue	-		20		
Research and development	550	2	2,240		
General and administrative	3,564	5	5,739		
Loss on impairment of assets			-		
Total operating expenses	4,114	7	7,999		
Loss from operations	(4,114)	8)	3,005)		
Other income (expense):					
Interest income	-		1		
Interest expense	-		-		
Other income (expense), net	(8,746)	(8)	3,489)		
Loss before provision for income taxes	(12,860)	(16	5,493)		
Provision for income taxes	-		-		
Net loss	(12,860)	\$ (16	5,493)		

Case 22-10506-JKS Doc 206 Filed 09/22/22 Page 12 of 13

Zosano Pharma - Schedule of Payments to Professionals For the Month Ended Aug 31, 2022

				Court Approved (1)			Retainer Applied						Paid by Estate					
Name of Professional	<u>Role</u>	<b>Date of Retention</b>	Retainer Received	Compensation	Expenses	Current Per	<u>iod</u> <u>Cι</u>	umulative	Compen	sation	Expense	S Current Per	iod	<u>Cumulative</u>	Compensat	ion Expenses Cur	rent Period	<u>Cumulative</u>
Kurtzman Carson Consultants LL	Claims and Noticing Agent	6/1/2022	\$ 50,000	\$ -	\$ -	\$	- \$	-	\$	-	\$ -	\$	-	\$ 13,260	\$ 70	,473 \$ 37,931 \$	108,404	\$ 108,404

<sup>(1)</sup> Per the order authorizing rentention of Kurztman Carson Consultants LLC (KCC) as Claims and Noticing Agent (Docket No. 23), the Debtor is authorized to compensate KCC for its services and expenses without the need for KCC to file fee applications or otherwise seek Court approval.

# Zosano Pharma - Prepetition Payments For the Month Ended Aug 31, 2022

Date	Vendor	Description	Amount
8/1/2022	CDFT Sales Tax	Sales Tax	2,682.00
8/5/2022	Alfonso Lictao	Pre-Petition Vacation	12,204.13
8/5/2022	Mahmoud Ameri	Pre-Petition Vacation	609.38
8/18/2022	Jagdeep Singh	Pre-Petition Vacation	7,668.97
8/18/2022	Lu Liu	Pre-Petition Vacation	9,401.29
		Total	\$ 32,565.77